Promising Advances in Treating Neuromyelitis Optica

Neuromyelitis optica (NMO), a severe autoimmune disorder, has recently seen some hopeful developments.

If untreated, NMO can lead to significant disability, primarily caused by antibodies (AQP4-IgG) that attack astrocytes in the brain and spinal cord.

There’s a range of therapies available, but they often come with high costs, variable effectiveness, and potential side effects—plus, relapses can be frustratingly common.

Now, allogeneic hematopoietic cell transplantation (alloHCT) has shown promising results in treating two patients, according to researchers from Italy’s IRCCS San Raffaele Scientific Institute.

This method involves using donor stem cells to reset the patient’s immune system, enabling it to stop attacking its own body.

Both patients were 28 at the time of their treatment, and the outcomes have been remarkable.

After over 15 years of follow-up, the patients have remained free from relapses without any need for ongoing immunosuppression. Their quality of life has also improved significantly, with disease-related antibodies disappearing entirely.

The researchers observed, “Over more than 15 years of follow-up, both patients remained relapse-free… accompanied by enhanced quality of life.”

For the male patient, there have been notable improvements in his neurological health; he even has two children now and has, as the researchers put it, “resumed a normal life.”

The female patient hasn’t seen as dramatic a change, but she has reported a good quality of life, needing no further medication, and has regained some mobility in her arms.

The researchers point out that no current approved treatments allow patients to remain free of therapy while maintaining effective disease control.

This alloHCT technique has been referenced in treating other conditions like cancer and sickle-cell disease, and a few attempts have been made with NMO in the past. However, this study stands out as the longest follow-up period for alloHCT patients with NMO, ranging from 15 to 16 years.

Before the transplantation, both patients underwent chemotherapy to eliminate their existing immune system’s B cells, which produce the harmful AQP4-IgG antibodies.

As the new donor cells are administered, they multiply and help rebuild the body’s defenses without those dangerous antibodies.

It’s a drastic measure; the immune system shutting down and restarting can be risky.

But this study showcases that, when conducted carefully, this process can mitigate the impacts of neuromyelitis optica—though it’s worth noting these patients were chosen because previous treatments had failed.

The researchers state, “In this evolving therapeutic landscape, alloHCT should be considered within a balanced, individualized risk-benefit framework.” They emphasize its suitability for younger patients who’ve seen aggressive, treatment-resistant NMO.

The lengthy follow-up period speaks volumes about the long-term effects, even if the sample size was just two individuals.

That said, it hasn’t been without challenges. After the transplant, the male patient dealt with chronic immune deficiency that required antibody supplementation, and the female patient developed a bladder cancer that was surgically treated. The precise cause of his health issue remains unclear, and there’s no solid evidence linking these complications directly to the transplant.

The research community is eager to explore how this treatment performs against other upcoming strategies.

With a range of immune “reset” treatments emerging, the field is slowly progressing. As the methods improve and risks are better managed, this could be an avenue worth pursuing.

The researchers concluded by stating that, under carefully chosen circumstances, immune system replacement could lead to long-term control of the disease, though larger studies are still needed to ensure safety and identify appropriate candidates.

This study appears in the journal Med.